Related Experiment Video

Updated: Dec 15, 2025

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.8K

Rational use of mucoactive medications to treat pediatric airway disease

R S N Linssen1, J Ma2, R A Bem1

  • 1Pediatric Intensive Care Unit, Amsterdam UMC, Emma Children's Hospital, Location AMC, Amsterdam, the Netherlands.

Paediatric Respiratory Reviews
|July 13, 2020
PubMed

Insights

This review examines mucoactive medications for childhood airway diseases like cystic fibrosis and asthma, focusing on their effectiveness in clearing mucus and future research needs.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Airway secretion retention is common in pediatric respiratory illnesses such as cystic fibrosis (CF), pneumonia, and asthma.
  • Effective clearance of airway mucus is crucial for managing these conditions.

Purpose of the Study:

  • To review the current evidence supporting the use of mucoactive medications in pediatric airway diseases.
  • To explore future research directions for optimizing mucoactive therapies.

Main Methods:

  • Systematic review of existing literature on mucoactive medications.
  • Analysis of clinical trial data and observational studies.
  • Synthesis of evidence for various pediatric airway diseases.

Main Results:

  • Mucoactive medications show variable success in improving airway secretion clearance.
  • Evidence supports their use in specific conditions like CF, but further research is needed for others.
  • Current treatments present challenges and opportunities for therapeutic advancement.

Conclusions:

  • Mucoactive agents are integral to managing pediatric airway diseases with mucus retention.
  • Further research is essential to refine efficacy and identify optimal therapeutic strategies.
  • Personalized approaches to mucoactive therapy may improve patient outcomes.

Keywords:
Airway diseasesCystic fibrosisDornaseMucoactive medicationsMucolyticsSputum

More Related Videos

In vivo Evaluation of Mucociliary Clearance in Mice06:35

In vivo Evaluation of Mucociliary Clearance in Mice

Published on: December 18, 2020

4.7K
Use of the EpiAirway Model for Characterizing Long-term Host-pathogen Interactions08:12

Use of the EpiAirway Model for Characterizing Long-term Host-pathogen Interactions

Published on: September 2, 2011

12.0K

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
529
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
764
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
614
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
899
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.2K